Patents by Inventor Kyle Schlunegger

Kyle Schlunegger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-VEGF antibody compositions and methods
    Patent number: 9421256
    Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: August 23, 2016
    Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.
    Inventors: Anita Kavlie, Kyle Schlunegger
  • Anti-VEGF antibody compositions and methods
    Patent number: 8394943
    Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: March 12, 2013
    Assignees: Affitech Research AS, Peregrine Pharmaceuticals, Inc.
    Inventors: Anita Kavlie, Kyle Schlunegger
  • Anti-VEGF Antibody Compositions and Methods
    Publication number: 20120064001
    Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
    Type: Application
    Filed: September 6, 2011
    Publication date: March 15, 2012
    Applicants: AFFITECH RESEARCH AS, PEREGRINE PHARMACEUTICALS, INC.
    Inventors: Anita Kavlie, Kyle Schlunegger
  • Anti-VEGF antibody compositions and methods
    Patent number: 8034905
    Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: October 11, 2011
    Assignees: Affitech Research, AS, Peregrine Pharmaceuticals, Inc.
    Inventors: Anita Kavlie, Kyle Schlunegger
  • Anti-VEGF Antibody Compositions and Methods
    Publication number: 20090175791
    Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
    Type: Application
    Filed: November 7, 2008
    Publication date: July 9, 2009
    Applicants: Peregrine Pharmaceuticals, Inc., Affitech A/S
    Inventors: Anita Kavile, Kyle Schlunegger